Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human induced tumor protein (HITP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HITP. The invention also provides for the production and use of substantially purified HITP in pharmaceutical compositions to force differentiation and to stop cell division in cancerous cells. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding HITP and the anti-HITP antibodies which specifically bind to HITP.

Abstract: The present invention involves a process of purifying and recovering a recombinant protein from a suspension of cells. The process of the present invention involves extracting a recombinant protein from a concentrated suspension of cells using a water-miscible organic solvent, isolating the recombinant protein from the suspension of cells, concentrating the recombinant protein to remove the water-miscible organic solvent, precipitating the recombinant protein using an acid, washing the recombinant protein with the salt or free form of a suitable organic acid and recovering the recombinant protein.

Abstract: The present invention relates to drug screening assays which provide a systematic and practical approach for the identification of candidate agents able to inhibit ubiquitin-mediated degradation of a cell-cycle regulatory protein, such as p53, p27, myc, fos, MAT.alpha.2, or cyclins. The invention further relates to novel ubiquitin-conjugating enzymes, and uses related thereto.

Abstract: This invention relates to a novel calpain having a proteolytic activity, its partial peptide or a salt either of them, a DNA coding for the protein, a recombinant vector comprising the DNA, a transformant carrying the recombinant vector, a process for producing the protein, a pharmaceutical composition comprising the DNA, an antibody against the protein, a method for screening for a compound which activates or inhibits a proteolytic activity of the protein, a kit for screening for the compound, and a compound which activates or inhibits a proteolytic activity of the protein which is identified by the screening method or the kit. The DNA coding for the protein of the present invention can be used as a therapeutic and prophylactic composition for a variety of diseases including tumor, cerebral apoplexy, cerebral infarction, subarachnoid hemorrhage, Alzheimer's disease, myodystrophy, cataract, ischemic heart disease, atherosclerosis, arthritis, and collagen disease.

Abstract: Expression of the polynucleotide molecule, Psx, is restricted to placenta, and in particular, to placenta trophoblast cell layers during embryogenesis. The expression pattern of Psx is exploited to detect trophoblast specific lineages, such as labyrinthine trophoblast layer and giant cells. The invention provides an isolated DNA molecule encoding Psx protein, and chimeric constructs, vector and host cells containing the isolated DNA. Also provided is a method for identifying putative abortion-inducing agents, which may offer an alternative to surgical abortion.

Abstract: The invention provides for use of selective inhibitors of GSK3 for treatment of diseases that are mediated by GSK3 activity, including non-insulin dependent diabetes mellitus (NIDDM) and Alzheimer's disease. Also described are methods of identifying inhibitors of GSK3 activity. The selective GSK3 inhibitor can be a peptide, peptoid, small organic molecule, or polynucleotide.

Abstract: The invention provides for use of selective inhibitors of GSK3 for treatment of diseases that are mediated by GSK3 activity, including non-insulin dependent diabetes mellitus (NIDDM) and Alzheimer's disease. Also described are methods of identifying inhibitors of GSK3 activity. The selective GSK3 inhibitor can be a peptide, peptoid, small organic molecule, or polynucleotide.

Abstract: A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH.sub.2 --KWKSFIKKLTTAVKKVLTTGLPALIS--COOH (SEQ ID NO:1) and NH.sub.2 --KWKSFIKKLTSAAKKVVTTAKPLISS--COOH (SEQ ID NO:2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.

Abstract: The present invention provides a novel method for the rapid isolation and identification of large numbers of novel enzyme substrates. The novel method provided by the present invention identifies substrates in tissue and/or cell extracts of a non-human model characterized as having an inactive enzyme. Without active enzyme, the substrates of this enzyme accumulate in the non-human model. The tissue or cell extract containing the enzyme substrate is then fractionated by passing the extract through an affinity column. The affinity column comprises an enzyme having similar specificity to the inactive enzyme, bound to a solid support. The affinity resin binds the enzyme substrate so that the substrate may be isolated from other proteins in the extract. The substrate of the enzyme may then be further identified by purifying and sequencing. Also provided by the present invention are novel substrates, and analogs of the substrates identified by the method of the present invention.

Abstract: A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides includeNH.sub.2 -KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO:1)andNH.sub.2 -KWKSFIKKLTSAAKKVVTTAKPLISS-COOH. (SEQ ID NO:2)Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.

Abstract: The method of the invention provides for the formation of a recombinant polypeptide which has been modified at the C-terminal end through the use of a transpeptidation process. The method is suitable for modifying recombinant polypeptides of any source including those which may be commercially available, those derived from recombinant single copy or multicopy polypeptide constructs, or those derived from single or multicopy recombinant fusion protein constructs. The transpeptidation reaction involves contacting an endopeptidase enzyme with a recombinant polypeptide to substitute an addition unit, of one or more amino acids, for a leaving unit, linked to a core polypeptide through a cleavage site recognized by the endopeptidase enzyme. Recombinant polypeptides derived from multicopy polypeptide constructs may be cleaved from the multicopy polypeptide at the N-terminal and C-terminal ends and simultaneously under go substitution of the leaving unit by the desired addition unit.

Abstract: The present invention relates to methods for immunoassay of analytes employing mutant glucose-6-phosphate dehydrogenase (G6PDH) enzymes as labels. In particular, the invention relates to the use of conjugates of an analyte or analyte analog and a mutant NAD.sup.+ dependent G6PDH differing from any precursor G6PDH by the deletion, substitution, or insertion, or any combination thereof of at least one amino acid per subunit. The invention also involves the construction of several mutations in precursor glucose-6-phosphate dehydrogenase (G6PDH) enzymes. Typically, the mutations involve deletion or substitution of one or more lysine residues, or introduction of one or more cysteine residues by insertion of cysteine to precursor G6PDH or substitution of precursor G6PDH amino acids residues with cysteine.

Abstract: The invention provides a new human phosphatidylinositol transfer protein gamma (PITP.gamma.) and polynucleotides which identify and encode PITP.gamma.. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of PITP.gamma..

Abstract: The present invention provides a transgenic animal assay system which provides a model system for testing for, and treatment of, cholinergic deficits and imbalances in mammals such as cognitive functioning in Alzheimer's patients, certain types of retinal photoreceptor degeneration, hematopoietic disorders, and screening for and susceptibility to anti-cholinesterase compounds. The transgenic animals and progeny thereof are transformed with a recombinant expression vector of the present invention. The recombinant expression vector comprises a DNA sequence encoding a heterologous cholinesterase (ChE) enzyme and promoter.

Abstract: The present invention relates to compositions and methods for secretion of functional proteins in a soluble form by host cells. In particular, the invention relates to membrane targeting and translocation proteins, MttA, MttB and MttC and to variants and homologs thereof. The membrane targeting and translocation proteins are useful in targeting protein expression to the periplasm of gram negative bacteria and to extracellular media of other host cells. Such expression allows secretion of expressed proteins of interest in a functional and soluble form, thus facilitating purification and increasing the yield of functional proteins of interest.

Abstract: The present invention provides polynucleotides which identify and encode a novel human nucleic acid binding protein (NABP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NABP. The invention also provides for the use of substantially purified NABP or its antagonists, in pharmaceutical compositions for the treatment of diseases associated with the expression of NABP. Additionally, the invention provides for the use of antisense molecules to NABP in pharmaceutical compositions for treatment of diseases associated with the expression of NABP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding NABP or anti-NABP antibodies which specifically bind to NABP.

Abstract: The present invention provides a protein regulating the sensitivity of fungus to an antimycotic aureobasidin, a gene coding for this protein, the use thereof, an antibody for the protein and the use thereof. The invention is useful in the diagnosis and treatment for diseases including mycoses.The invention also provides a novel chromosome integration vector capable of imparting a novel selective marker of a drug resistance to a fungal transformant, a transformant transformed with this vector and a process for producing the same. In particular, it provides a protein capable of imparting the resistance to aureobasidin and acting as a selective marker and a DNA coding for the same.

Abstract: The present invention provides a human novel RAB protein (SRAB) and polynucleotides which identify and encode SRAB. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with expression of SRAB.

Abstract: The invention provides a human preprotachykinin B (PPT-B) and polynucleotides which identify and encode PPT-B. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of PPT-B.

Abstract: The invention relates to the use of von Willebrand Factor (vWF) with a prolonged biological half-life for the production of a preparation for stabilization of blood coagulation Factor VIII (FVIII:C) in a mammal. Additionally, a pharmaceutical preparation is provided comprising a biologically active FVIII:C/vWF complex with improved pharmokinetic properties, said complex containing a vWF with a prolonged biological half-life.